We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Merus Nv
1 own
8 watching
Current Price
$16.86
$0.35
(2.12%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
780.67M
52-Week High
30.81
52-Week Low
12.03
Average Volume
0.47M
Dividend Yield
--
P/E Ratio
--
Market Capitalization780.67M52-Week High30.8152-Week Low12.03Average Volume0.47MDividend Yield--P/E Ratio--What does the Merus Nv do?
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Read More
How much money does Merus Nv make?
News & Events about Merus Nv.
Globe Newswire
7days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive ...
Globe Newswire
1month ago
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (NRG1+) cancer have been treated with zenocutuzumab (Zeno) monotherapy - Petosemtamab clinical update planned for first half of 2023 - MCLA-129 clinical update planned for second half of 2023 - Based on the Companys current...
Zolmax
2 months ago
Summit Therapeutics (NASDAQ:SMMT Get Rating) and Merus (NASDAQ:MRUS Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, ...
Globe Newswire
3 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive ...
Market News Video
3 months ago
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two ...
Frequently Asked Questions
Frequently Asked Questions
What is Merus Nv share price today?
Can Indians buy Merus Nv shares?
How can I buy Merus Nv shares from India?
Can Fractional shares of Merus Nv be purchased?
What are the documents required to start investing in Merus Nv stocks?
What is today’s traded volume of Merus Nv?
What is today’s market capitalisation of Merus Nv?
What is the 52-Week High and Low Range of Merus Nv?
What percentage is Merus Nv down from its 52-Week High?
What percentage is Merus Nv up from its 52-Week Low?
Current Price
$16.86
$0.35
(2.12%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.